Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea flag South Korea · Delayed Price · Currency is KRW
63,500
+1,600 (2.58%)
At close: Aug 28, 2025

Next Biomedical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
Operating Revenue
12,1639,5434,8822,7952,2672,261
Upgrade
Other Revenue
----0--0
Upgrade
12,1639,5434,8822,7952,2672,261
Upgrade
Revenue Growth (YoY)
110.73%95.46%74.67%23.28%0.29%182.32%
Upgrade
Cost of Revenue
4,2873,7872,8132,6182,9982,433
Upgrade
Gross Profit
7,8765,7552,069177.49-731.09-172.71
Upgrade
Selling, General & Admin
3,4772,6102,4072,2462,8661,994
Upgrade
Research & Development
7,0706,6224,7833,5793,2452,720
Upgrade
Other Operating Expenses
26.4821.5120.0419.2918.3910.61
Upgrade
Operating Expenses
10,6469,3307,2965,9466,2394,832
Upgrade
Operating Income
-2,769-3,575-5,226-5,768-6,970-5,004
Upgrade
Interest Expense
-476.72-520.06-574.37-360.41-1,413-1,535
Upgrade
Interest & Investment Income
741.98634.82574.31200.41138.6635.87
Upgrade
Currency Exchange Gain (Loss)
229.771,1280.5663.6390.33-77.31
Upgrade
Other Non Operating Income (Expenses)
5,0575,074-2,429268.61-8,494-17,835
Upgrade
EBT Excluding Unusual Items
2,7832,742-7,655-5,596-16,648-24,416
Upgrade
Gain (Loss) on Sale of Investments
-217.98113.58133.56-102.48-65.86-34.61
Upgrade
Gain (Loss) on Sale of Assets
9.784.24-5.2969.580.1
Upgrade
Asset Writedown
----38.72-0.8-27.31
Upgrade
Pretax Income
2,5742,860-7,522-5,732-16,645-24,477
Upgrade
Net Income
2,5742,860-7,522-5,732-16,645-24,477
Upgrade
Net Income to Common
2,5742,860-7,522-5,732-16,645-24,477
Upgrade
Shares Outstanding (Basic)
876654
Upgrade
Shares Outstanding (Diluted)
876654
Upgrade
Shares Change (YoY)
29.11%17.78%1.10%28.34%13.05%199.99%
Upgrade
EPS (Basic)
323.36396.71-1198.00-923.00-3440.00-5719.00
Upgrade
EPS (Diluted)
-272.78-262.00-1198.00-923.00-3440.00-5719.00
Upgrade
Free Cash Flow
-4,433-1,640-4,225-8,403-6,101-4,003
Upgrade
Free Cash Flow Per Share
-544.01-221.77-672.87-1353.18-1260.87-935.17
Upgrade
Gross Margin
64.75%60.31%42.38%6.35%-32.25%-7.64%
Upgrade
Operating Margin
-22.77%-37.46%-107.05%-206.37%-307.42%-221.36%
Upgrade
Profit Margin
21.16%29.97%-154.06%-205.07%-734.13%-1082.74%
Upgrade
Free Cash Flow Margin
-36.44%-17.18%-86.53%-300.65%-269.08%-177.05%
Upgrade
EBITDA
-2,268-3,082-4,759-5,305-6,537-4,431
Upgrade
EBITDA Margin
-18.64%-32.30%-97.48%-189.79%-288.30%-195.98%
Upgrade
D&A For EBITDA
501.62492.36467.32463.41433.53573.79
Upgrade
EBIT
-2,769-3,575-5,226-5,768-6,970-5,004
Upgrade
EBIT Margin
-22.77%-37.46%-107.05%-206.37%--221.36%
Upgrade
Advertising Expenses
-171.98196.959.6476.258
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.